Camilla Jandus

Programmed cell death-1: from a T-cell immune checkpoint to a regulator of Natural Killer cell biology

Fabiana De Franco, Marco Greppi, Valentina Obino, Federico Rebaudi et autres

it, fr, ca, ch (code pays fourni par la source)

Addendum: Neural anticipation of virtual infection triggers an immune response

S Trabanelli, Michel Akselrod, Julia Fellrath, Giulia Vanoni et autres

ch, it, gb, fr (code pays fourni par la source)

KLRG1 identifies circulating cytotoxic CD4 T cells with selective anti-tumor function in human cancer

Mara Cenerenti, Josep Garnica, Margaux Saillard, Paul Gueguen et autres

ch, fr, gb, es (code pays fourni par la source)

Figure S1 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard et autres

Figure S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard et autres

Figure S7 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard et autres

Data from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard et autres

Figure S5 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard et autres

Figure S10 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard et autres

Figure S4 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard et autres

Supplementary Table S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard et autres

Figure S6 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard et autres